271 related articles for article (PubMed ID: 33777142)
1.
Hsieh YC; Chang TK; Su WC; Huang CW; Tsai HL; Chen YC; Li CC; Chen PJ; Yin TC; Ma CJ; Wang JY
J Oncol; 2021; 2021():6686517. PubMed ID: 33777142
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
[No Abstract] [Full Text] [Related]
3. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting.
Lu CY; Huang CW; Wu IC; Tsai HL; Ma CJ; Yeh YS; Chang SF; Huang ML; Wang JY
Transl Oncol; 2015 Dec; 8(6):474-9. PubMed ID: 26692528
[TBL] [Abstract][Full Text] [Related]
5. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
Trials; 2016 Jan; 17():46. PubMed ID: 26811156
[TBL] [Abstract][Full Text] [Related]
6. Comparison of
Tsai HL; Chen YC; Yin TC; Su WC; Chen PJ; Chang TK; Li CC; Huang CW; Wang JY
Oncol Res; 2022 May; 29(1):47-61. PubMed ID: 35177165
[No Abstract] [Full Text] [Related]
7. Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to
Li CC; Chang TK; Chen YC; Tsai HL; Huang CW; Su WC; Ma CJ; Yin TC; Chen PJ; Wang JY
Cancer Manag Res; 2022; 14():1541-1549. PubMed ID: 35498511
[TBL] [Abstract][Full Text] [Related]
8. Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).
El-Deiry WS; Winer A; Slifker M; Taylor S; Adamson BJS; Meropol NJ; Ross EA
Front Oncol; 2019; 9():142. PubMed ID: 30923702
[No Abstract] [Full Text] [Related]
9. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
[TBL] [Abstract][Full Text] [Related]
10. Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H; Ogimi T; Chan LF; Kamei Y
Oncology; 2020; 98(9):637-642. PubMed ID: 32474564
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
12. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E;
ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671
[TBL] [Abstract][Full Text] [Related]
13. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
[TBL] [Abstract][Full Text] [Related]
16. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Sanoff HK; Deal AM; Patel J; Sorah JD; Gaddy J; O'Neil B; Turk A; Irvin W; Boles J; Lee MS; McRee A; Wardell AC; Weck KE; Basch E; Wood WA; Innocenti F
Oncologist; 2024 Jun; ():. PubMed ID: 38837045
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial.
Zhang X; Duan R; Wang Y; Liu X; Zhang W; Zhu X; Chen Z; Shen W; He Y; Wang HQ; Huang M; Wang C; Zhang Z; Zhao X; Qiu L; Luo J; Sheng X; Guo W
Ther Adv Med Oncol; 2022; 14():17588359211068737. PubMed ID: 35069808
[TBL] [Abstract][Full Text] [Related]
19. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Manfredi S; Bouché O; Rougier P; Dahan L; Loriot MA; Aparicio T; Etienne PL; Lafargue JP; Lécaille C; Legoux JL; Le Malicot K; Maillard E; Lecomte T; Khemissa F; Breysacher G; Michel P; Mitry E; Bedenne L
Mol Cancer Ther; 2015 Dec; 14(12):2782-8. PubMed ID: 26494856
[TBL] [Abstract][Full Text] [Related]
20. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]